[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518772":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":22,"collaborators":7,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":7,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":33,"phases":7,"briefSummary":34,"conditions":35,"keywords":7,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Biohaven Pharmaceuticals, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Troriluzole","BHV-4157 140mg, 200mg or 280mg once daily by mouth.",[14],"BHV-4157",[16],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Early Access Care","CONTACT","1-203-441-7938","175","Troriluzole.EAP@earlyaccesscare.com",{"type":23,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100518772","expanded-access-protocol-of-troriluzole-in-patients-with-spinocerebellar-ataxia-sca-100518772",false,"NCT06034886","Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","Intermediate-Size Patient Population Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","Key Inclusion Criteria:\n\n* Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.\n* Adequate hepatic function.\n\nKey Exclusion Criteria:\n\n* Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.\n* Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.","ALL","18 Years","EXPANDED_ACCESS","The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).",[36,37],"SCA","Spinocerebellar Ataxias","AVAILABLE","2026-01-08",{"date":41,"type":42},"2026-01-09","ACTUAL",{"name":5,"class":6}]